Canopy Growth Corp Stock Price, News & Analysis

Canopy Growth (Nasdaq: CGC) reported strong Q1 FY2026 financial results, with total revenue increasing 9% year-over-year to $72.1 million. The company's Canada adult-use cannabis revenue surged 43% to $27 million, driven by increased distribution and strong demand for new products, particularly Claybourne infused pre-roll joints.

The company achieved $17 million of its planned $20 million annualized savings target since March 2025, with SG&A expenses down 21% year-over-year. However, gross margin decreased to 25% from 35% in Q1 FY2025, primarily due to lower Storz & Bickel sales and product mix shifts. The company reported a net loss of $41.5 million, showing a 68% improvement from the previous year.

Additionally, Canopy Growth announced the appointment of Shan Atkins to its Board of Directors, bringing extensive retail strategy and operations experience.

Canopy Growth (Nasdaq: CGC) has expanded its medical cannabis portfolio in Australia with the launch of its 7ACRES brand. The company introduced two high-THC sativa strains: Ultra Jack and Jack Frost, available in 10g flower formats.

The expansion complements Canopy's existing Australian presence, which includes Tweed flower products and Spectrum Therapeutics oils. This launch leverages the company's improved global supply chain and Canadian production capabilities to strengthen its international medical platform.

Canopy Growth (Nasdaq: CGC) has appointed Miles Worne as Managing Director of European Markets, effective August 11, 2025. Worne, who previously served as President of Curaleaf International, brings over 20 years of experience in cannabis, healthcare, and consumer sectors.

The appointment aligns with Canopy Growth's strategic focus on European expansion, particularly in established medical markets. The company's European operations are supported by EU-GMP certified supply from its Kincardine facility, processing capabilities at St. Leon-Rot in Germany, and a global supply chain infrastructure.

Canopy Growth (NASDAQ:CGC) has announced a significant debt reduction initiative through an agreement with its lenders. The company will make three prepayments totaling US$50 million to reduce its Senior Secured Term Loan by March 31, 2026.

The prepayments will be made in three installments: US$25 million by July 31, 2025, US$10 million by December 31, 2025, and US$15 million by March 31, 2026. This debt reduction is expected to lower the company's annual cash interest expense by US$6.5 million.

Additionally, Canopy USA received consent to secure US$22 million in additional funding for Acreage Holdings and its subsidiaries.

Canopy Growth (NASDAQ:CGC) has scheduled its first quarter fiscal 2026 financial results release for August 8, 2025, before market open. The company will host an audio webcast at 10:00 AM ET on the same day, featuring CEO Luc Mongeau and Interim CFO Tom Stewart.

The webcast will be available live and accessible for replay until November 6, 2025 at 11:59 PM ET through the company's online portal.

Canopy Growth (Nasdaq: CGC) has launched Deep Space Infused pre-rolls, combining high-quality flower with liquid diamonds and THCA diamonds to achieve THC levels above 60%. The product comes in a 3x0.5g format with two flavors: Milky Way Melon Infused and Big Bang Berry Infused.

The launch is part of Canopy's strategy to expand in the fast-growing pre-roll category, particularly in the infused segment. This follows recent Deep Space beverage and gummy innovations, building on the success of Claybourne's Frosted Flyers launched in November 2024.

The products are now available at licensed retailers across select regions in Canada, including the Spectrum Therapeutics online store for medical consumers.

Canopy Growth (Nasdaq: CGC) has appointed Tom Stewart as Interim Chief Financial Officer, effective immediately. Stewart, who joined the company in 2019 as Chief Accounting Officer, brings over 20 years of experience in operational finance and accounting leadership, including 10 years at Constellation Brands.

Stewart succeeds Judy Hong, who served as CFO since April 2022 and helped improve the company's capital structure. The appointment aligns with Canopy Growth's FY26 strategy, focusing on operational efficiency, disciplined capital management, and building a sustainable, performance-led business. The company has initiated a search for a permanent CFO.

Storz & Bickel, a subsidiary of Canopy Growth Corporation (NASDAQ: CGC), has been awarded 'Equipment Provider of the Year' at the 2025 Business of Cannabis Awards during the Cannabis Europa conference in London.

The award recognizes the company's excellence in vaporization technology, highlighting products like the iconic VOLCANO tabletop vaporizer and the new VENTY device, which features 20-second heat-up and adjustable airflow up to 20 L/min. Storz & Bickel's vaporizers are available in over 120 countries and comply with ISO 13485 standards.

The company has also received multiple other recent accolades, including "Vaporizer of the Year" at The EMJAYs and "Best Portable Vaporizer" by Vaping360 for the VENTY device.

Canopy Growth (CGC) reported Q4 FY2025 and full-year results showing mixed performance. Q4 net revenue decreased 11% YoY to $65M, while Canada cannabis revenue grew 4%, led by 13% growth in medical cannabis. The company reduced total debt by $293M (49%) during FY2025. Operating loss improved 83% to $18M in Q4, with Adjusted EBITDA loss improving 39% to $9M. The company implemented strategic changes including unifying global medical cannabis operations and identifying $20M in cost savings. Storz & Bickel revenue declined 23% in Q4 but grew 4% for the full year. International cannabis revenue fell 35% in Q4 due to regulatory challenges in Poland. Management is focused on achieving positive Adjusted EBITDA in the near term through growth in medical cannabis, improved margins in adult-use, and cost reductions.